Attention:

Certain features of Sigma-Aldrich.com will be down for maintenance the evening of Friday August 18th starting at 8:00 pm CDT until Saturday August 19th at 12:01 pm CDT.   Please note that you still have telephone and email access to our local offices. We apologize for any inconvenience.

Glutamine Metabolism is Dysregulated in Many Cancer Cells

Proliferatively active cells require both a source of carbon and of nitrogen for the synthesis of macromolecules. Although a large proportion of tumor cells utilize aerobic glycolysis and shunt metabolites away from mitochondrial oxidative phosphorylation, many tumor cells exhibit increased mitochondrial activity. In these cells, glutamine uptake is markedly enhanced and far exceeds the metabolic requirements of the cell. Much of this glutamine is inefficiently used and secreted from the cells as lactic acid, ammonia, or alanine, a situation with many parallels to the inefficient metabolism of glucose by many cancer cells.1 Glutamine is used by the cell for both bioenergetic and biosynthetic needs. Glutamine can be used as an amino acid for protein synthesis, as a carbon source, or as the primary nitrogen donor for multiple essential biosynthetic reactions in the cell. Once taken up by the cell, much of the glutamine is converted to glutamate by mitochondrial glutaminase, an enzyme whose levels are often upregulated in tumors and tumor lines.2,3 Glutaminase is required for the proliferation of both a human B lymphoid tumor line and PC3 prostrate cancer cells, suggesting that targeting this pathway is a viable therapeutic option.4,5 Both glutamine and glutamate contribute to anabolic metabolism; glutamine supplies nitrogen for nucleotide and hexosamine synthesis while glutamate is the nitrogen donor for the synthesis of many nonessential amino acids. Glutamate can be used to support the production of NADPH or converted to the metabolic intermediates pyruvate and α-ketoglutarate.

It is now well appreciated that many of the signaling pathways that promote oncogenesis also reprogram glutamine metabolism, and in many cells the dependence on glutamine is absolute, a condition termed glutamine addiction.6 The most well characterized oncogene driving enhanced glutamine metabolism is C-Myc. Many cancers exhibit increased expression of the transcription factor MYC and MYC has been implicated in the regulation of many genes involved in energy metabolism, mitochondrial biogenesis, and cell cycle regulation.4 In a study with an inducible C-Myc transgene, C-Myc expression resulted in the induction of many key glutamine metabolic proteins including glutamine transporters and glutaminase.7

The reliance of many cells on aerobic glycolysis results in a decrease in the amount of pyruvate entering the tricarboxylic acid (TCA) cycle because metabolites upstream of pyruvate are being fed into other biosynthetic pathways and pyruvate is converted to lactic acid. Since metabolites generated during the TCA cycle are required for the synthesis of lipids, nonessential amino acids, and nucleotides, an actively dividing cell requires a mechanism for replenishing this cycle. Many cancer cells rely on glutamate anaplerosis to refill the TCA cycle. Glutamate enters the TCA cycle via its conversion to α-ketoglutarate by the actions of either transaminases or glutamante dehydrogenase.2 Malate and citrate created by the TCA cycle are then available for further biosynthetic pathways.

 

O-(Carboxymethyl) hydroxyl amine hemihydrochloride
(Aminooxy) acetic acid hemihydrochloride;
(Carboxymethoxy) amine hemihydrochloride;
Hydroxylamine-O-acetic acid hemihydrochloride
[2921-14-4] NH2OCH2COOH • 0.5HCl FW 109.30
• 98%
C13408-1G glass btl 1 g
C13408-10G glass btl 10 g
C13408-25G glass btl 25 g

 

6-Diazo-5-oxo-l-norleucine
• crystalline
DON is used to study mechanisms of glutamine utilizing enzymes such as carbamoyl phosphate synthase and cytidine triphosphate synthase.
store at −20 °C
D2141-5MG 5 mg
D2141-25MG 25 mg

 

Dimethyl 2-oxoglutarate
Dimethyl α-ketoglutarate [13192-04-6]
CH3O2CCH2CH2COCO2CH3 FW 174.15
• 96%
349631-5G 5 g

 

(−)-Epigallocatechin gallate
EGCG; (−)-cis-3,3’,4’,5,5’,7-Hexahydroxy-flavane-3-gallate;
(−)-cis-2-(3,4,5-Trihydroxyphenyl)-
3,4-dihydro-1(2H)- benzopyran-3,5,7-triol 3-gallate [989-51-5] C22H18O11 FW 458.37
• ≥95%, from green tea
ECGG inhibits fatty acid synthase and glutamate dehydrogenase activity.
E4143-50MG 50 mg

 

Perphenazine
Inhibits glutamate dehydrogenase in vitro.
P6402-1G 1 g
P6402-5G 5 g

 

Anti-GLS

Anti-GLS: Cat. No. HPA036223: Immunohistochemical staining of human kidney shows strong cytoplasmic positivity in cells in tubules.

Anti-PPAT

Anti-PPAT: Cat. No. HPA036092: Immunohistochemical staining of human colon shows moderate cytoplasmic positivity in glandular cells.

Materials

     

References

  1. Barger, J. F. and Plas, D. R. Balancing Biosynthesis and Bioenergetics: Metabolic Programs in Oncogenesis. Endocrine-Related Cancer. 17, R287-R304 (2010).
  2. DeBerardinis, R. J. and Cheng, T. Q’s next: The Diverse Functions of Glutamine in Metabolism, Cell Biology, and Cancer. Oncogene, 29, 313-324 (2010).
  3. Levine, A. J. and Puzio-Kuter, A. M. The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes. Science, 330, 1340-1344 (2010).
  4. Dang, C.V. Re-tinking the Warburg Effect with Myc Micro-Managing Glutamine Metabolism. Cancer Res., 70, 859-862 (2010).
  5. Dang, C.V. et al. MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Options. Clin Cancer Res., 15, 6479-6483 (2009).
  6. Wise, D. R. and Thompson, C. B. Glutamine Addiction: A New Therapeutic Target in Cancer. Trends. Biochem. Sci. 35, 427-433 (2010).
  7. Wise, D. R. et al. Myc Regulates a Transcriptional Program that Stimulates Mitochondrial Glutaminolysis and Leads to Glutamine Addiction. Proc. Natl. Acad. Sci. USA., 105, 18782-18787 (2008).

 

Related Links